AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11806300 — intervention group
Group type: COMPARATOR
Intervention: Substitutive hormonotherapy of post‐menopausal women
Number of subjects: 0
Study 9923567 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etoposide (50 mg/m2 daily for 21 days)
Number of subjects: 32
Study 9923567 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal sampling strategy (1, 4, and 24 h after administration)
Number of subjects: 32
Study 7994805 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 41021
Study 7994805 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Streptokinase and TPA)
Number of subjects: 41021
Study 7994805 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated TPA
Number of subjects: 41021
Study 7994805 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow grade 0 or 1
Number of subjects: 41021
Study 7994805 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow grade 2
Number of subjects: 41021
Study 7994805 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow grade 3
Number of subjects: 41021
Study 7994805 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall early deaths
Number of subjects: 41021
Study 7994805 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall later deaths
Number of subjects: 41021
Study 3181102 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupines
Number of subjects: 35
Study 3181102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid 30 mg
Number of subjects: 35
Study 3181102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid 60 mg
Number of subjects: 35
Study 29437621 — intervention group
Group type: EXPERIMENTAL
Intervention: Murepavadin (single ascending dose)
Number of subjects: 60
Study 29437621 — intervention group
Group type: EXPERIMENTAL
Intervention: Murepavadin (multiple ascending doses)
Number of subjects: 60
Study 29437621 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single ascending dose)
Number of subjects: 60
Study 29437621 — intervention group
Group type: COMPARATOR
Intervention: Placebo (multiple ascending doses)
Number of subjects: 60
Study 28659213 — intervention group
Group type: COMPARATOR
Intervention: Usual health messages (UHM)
Number of subjects: 3186
Study 28659213 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding counselling (BFC)
Number of subjects: 3186
Study 26377496 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual transplant patient education plus ten additional weekly 30‐min education/counseling sessions about immunosuppressive drugs and behavioral changes
Number of subjects: 111
Study 23221401 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan
Number of subjects: 0
Study 23221401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21792296 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ACTH gel 80 U/day for five days
Number of subjects: 20
Study 21792296 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ACTH gel 80 U/day for five days
Number of subjects: 20
Study 21792296 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular ACTH gel
Number of subjects: 20
Study 21792296 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous ACTH gel
Number of subjects: 20
Study 18055864 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine (100 mg/m² per course every 4 weeks)
Number of subjects: 3
Study 17065887 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon anesthesia (1 minimum alveolar concentration)
Number of subjects: 12
Study 17065887 — intervention group
Group type: COMPARATOR
Intervention: Control group (propofol only)
Number of subjects: 12
Study 14586800 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg alendronate daily
Number of subjects: 80
Study 14586800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 10487558 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden during radiotherapy
Number of subjects: 69
Study 10487558 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine during radiotherapy
Number of subjects: 69
Study 10487558 — intervention group
Group type: COMPARATOR
Intervention: Control group (no xerostomy prevention therapy)
Number of subjects: 69
Study 8533995 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine 0.8 g/d
Number of subjects: 264
Study 8533995 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine 1.6 g/d
Number of subjects: 264
Study 8533995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 8533995 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine 0.8 g/d (intention-to-treat)
Number of subjects: 264
Study 8533995 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine 1.6 g/d (intention-to-treat)
Number of subjects: 264
Study 8533995 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intention-to-treat)
Number of subjects: 264
Study 2265735 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 110
Study 2265735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 371741 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 80
Study 371741 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 30877658 — intervention group
Group type: EXPERIMENTAL
Intervention: 6α‐methylprednisolone acetate (MA) 40 mg
Number of subjects: 40
Study 30877658 — intervention group
Group type: COMPARATOR
Intervention: triamcinolone acetonide (TA) 40 mg
Number of subjects: 40
Study 28760939 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (<120 mm Hg)
Number of subjects: 7879
Study 28760939 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (<140 mm Hg)
Number of subjects: 7879
Study 28760939 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of OBPV
Number of subjects: 7879
Study 28760939 — intervention group
Group type: COMPARATOR
Intervention: Lowest quintile of OBPV
Number of subjects: 7879
Study 26142514 — intervention group
Group type: EXPERIMENTAL
Intervention: Total flavonoids from Lavandula angustifolia (LTF)
Number of subjects: 0
Study 26142514 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 25131073 — intervention group
Group type: EXPERIMENTAL
Intervention: ALEM (30 mg intraoperatively)
Number of subjects: 46
Study 25131073 — intervention group
Group type: COMPARATOR
Intervention: rATG (multiple doses starting intraoperatively)
Number of subjects: 46
Study 23006997 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted approach including audit and feedback, educational outreach visits, and patient-mediated interventions
Number of subjects: 32
Study 23006997 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted approach
Number of subjects: 32
Study 20817153 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + DCS (25 or 50 mg)
Number of subjects: 30
Study 20817153 — intervention group
Group type: COMPARATOR
Intervention: CBT + Placebo
Number of subjects: 30
Study 17928622 — intervention group
Group type: EXPERIMENTAL
Intervention: DynaMITE training environment with controlled motorized target movements
Number of subjects: 15
Study 15494612 — intervention group
Group type: EXPERIMENTAL
Intervention: Omental adipose tissue 20alpha‐HSD mRNA abundance
Number of subjects: 14
Study 15494612 — intervention group
Group type: EXPERIMENTAL
Intervention: Omental adipose tissue 3alpha‐HSD‐3 mRNA abundance
Number of subjects: 14
Study 15494612 — intervention group
Group type: EXPERIMENTAL
Intervention: Omental and subcutaneous adipose tissue 3alpha‐HSD activities
Number of subjects: 14
Study 15494612 — intervention group
Group type: EXPERIMENTAL
Intervention: Omental 20alpha‐HSD mRNA level
Number of subjects: 14
Study 15494612 — intervention group
Group type: EXPERIMENTAL
Intervention: Omental 3alpha‐HSD‐3 mRNA level
Number of subjects: 14
Study 11875724 — intervention group
Group type: EXPERIMENTAL
Intervention: UICC clinical stage II
Number of subjects: 324
Study 11875724 — intervention group
Group type: EXPERIMENTAL
Intervention: UICC clinical stage III
Number of subjects: 324
Study 11875724 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophilic infiltration (numerous eosinophils)
Number of subjects: 324
Study 9505188 — intervention group
Group type: EXPERIMENTAL
Intervention: ceftibuten 400 mg once daily
Number of subjects: 309
Study 9505188 — intervention group
Group type: COMPARATOR
Intervention: clarithromycin 500 mg twice daily
Number of subjects: 309
Study 7621455 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant combination therapy with flutamide and an LHRH agonist for 3 months
Number of subjects: 161
Study 7621455 — intervention group
Group type: COMPARATOR
Intervention: Radical prostatectomy alone
Number of subjects: 161
Study 3275673 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine mesylate/heparin sodium
Number of subjects: 148
Study 3275673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 30923970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided single-puncture arthrocentesis using modified double-lumen single-barrel needle
Number of subjects: 20
Study 30923970 — intervention group
Group type: COMPARATOR
Intervention: Single-puncture arthrocentesis with modified double-lumen single-barrel needle
Number of subjects: 20
Study 28524257 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-week oral language intervention programme
Number of subjects: 394
Study 28524257 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week oral language intervention programme
Number of subjects: 394
Study 28524257 — intervention group
Group type: COMPARATOR
Intervention: Untreated waiting control group
Number of subjects: 394
Study 28524257 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention programmes
Number of subjects: 394
Study 26488675 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-switching strategy (within 1 week)
Number of subjects: 79
Study 26488675 — intervention group
Group type: COMPARATOR
Intervention: Slow-switching strategy (within 4 weeks)
Number of subjects: 79
Study 26488675 — intervention group
Group type: EXPERIMENTAL
Intervention: Both fast and slow switching groups
Number of subjects: 79
Study 24320906 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal dentifrice (Hi Ora K, The Himalaya Drug Company)
Number of subjects: 73
Study 24320906 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice (The Himalaya Drug Company)
Number of subjects: 73
Study 21128151 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioner (GP) engagement in discussing lifestyle behaviors (smoking, alcohol, nutrition)
Number of subjects: 1029
Study 21128151 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient characteristics (gender and age)
Number of subjects: 1029
Study 21128151 — intervention group
Group type: EXPERIMENTAL
Intervention: Age as a predictor
Number of subjects: 1029
Study 21128151 — intervention group
Group type: EXPERIMENTAL
Intervention: GP-initiated discussions
Number of subjects: 1029
Study 17963740 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical sequences training
Number of subjects: 0
Study 17963740 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface distinctions and counting/repetition detection strategies
Number of subjects: 0
Study 20199402 — intervention group
Group type: EXPERIMENTAL
Intervention: WG (bathing with wash gel)
Number of subjects: 64
Study 20199402 — intervention group
Group type: EXPERIMENTAL
Intervention: C (bathing and cream)
Number of subjects: 64
Study 20199402 — intervention group
Group type: EXPERIMENTAL
Intervention: WG + C (bathing with wash gel plus cream)
Number of subjects: 64
Study 20199402 — intervention group
Group type: COMPARATOR
Intervention: B (bathing with water)
Number of subjects: 64
Study 15639176 — intervention group
Group type: EXPERIMENTAL
Intervention: OCD patients (n=18)
Number of subjects: 34
Study 15639176 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinson's disease patients (n=16)
Number of subjects: 34
Study 15639176 — intervention group
Group type: COMPARATOR
Intervention: Major depressive disorder patients (n=not specified)
Number of subjects: 34
Study 11277374 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg per day for up to 9 days in a reducing schedule)
Number of subjects: 14
Study 11277374 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 14
Study 9973793 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (group A)
Number of subjects: 113
Study 9973793 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis (group B)
Number of subjects: 113
Study 7603075 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (11 mg intravenous dose)
Number of subjects: 13
Study 3349554 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.012 mg.kg‐1 followed by edrophonium 0.8 mg.kg‐1 with a 1 min priming interval
Number of subjects: 72
Study 3349554 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.012 mg.kg‐1 followed by edrophonium 0.8 mg.kg‐1 with a 2 min priming interval
Number of subjects: 72
Study 3349554 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.012 mg.kg‐1 followed by edrophonium 0.8 mg.kg‐1 with a 3 min priming interval
Number of subjects: 72
Study 3349554 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 0.2 mg.kg‐1 followed by neostigmine 0.048 mg.kg‐1 with a 1 min priming interval
Number of subjects: 72
Study 3349554 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 0.2 mg.kg‐1 followed by neostigmine 0.048 mg.kg‐1 with a 2 min priming interval
Number of subjects: 72
Study 3349554 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 0.2 mg.kg‐1 followed by neostigmine 0.048 mg.kg‐1 with a 3 min priming interval
Number of subjects: 72
Study 3349554 — intervention group
Group type: EXPERIMENTAL
Intervention: Equipotent mixtures of antagonists administered as a single bolus dose
Number of subjects: 72
Study 31731609 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidance group (well‐structured and monitored nutrition and lifestyle counseling for six months)
Number of subjects: 160
Study 31731609 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidance group
Number of subjects: 160
Study 31731609 — intervention group
Group type: COMPARATOR
Intervention: GA group (one‐time general advice about lifestyle modification)
Number of subjects: 160
Study 29155973 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapering MTX (double-blind)
Number of subjects: 427
Study 29155973 — intervention group
Group type: COMPARATOR
Intervention: Stable MTX (double-blind)
Number of subjects: 427
Study 26702013 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer skis with reduced width and standing height
Number of subjects: 2
Study 26702013 — intervention group
Group type: EXPERIMENTAL
Intervention: Ski-snow friction force (FF)
Number of subjects: 2
Study 26702013 — intervention group
Group type: EXPERIMENTAL
Intervention: Ski-snow friction coefficient (CoeffF)
Number of subjects: 2
Study 24292879 — intervention group
Group type: EXPERIMENTAL
Intervention: Nap condition (two 15-min naps)
Number of subjects: 15
Study 24292879 — intervention group
Group type: COMPARATOR
Intervention: No-nap condition (no naps taken)
Number of subjects: 15
Study 22824474 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03A-adjuvanted A/California/7/2009 H1N1 vaccine (1.9 μg HA) administered at 21 days
Number of subjects: 306
Study 22824474 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03A-adjuvanted A/California/7/2009 H1N1 vaccine (1.9 μg HA) administered at 6 months
Number of subjects: 306
Study 22824474 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03A-adjuvanted A/California/7/2009 H1N1 vaccine (1.9 μg HA) administered at 21 days or 6 months
Number of subjects: 306
Study 20640949 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephonic psycho-social support, leaflet, and adherence diary intervention
Number of subjects: 279
Study 20640949 — intervention group
Group type: COMPARATOR
Intervention: Control group received only the leaflet
Number of subjects: 279
Study 16980349 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training group (TR; n = 43)
Number of subjects: 82
Study 16980349 — intervention group
Group type: COMPARATOR
Intervention: Untrained group (UTR; n = 39)
Number of subjects: 82
Study 15559609 — intervention group
Group type: EXPERIMENTAL
Intervention: TURP
Number of subjects: 96
Study 15559609 — intervention group
Group type: EXPERIMENTAL
Intervention: EVAP
Number of subjects: 96
Study 15559609 — intervention group
Group type: EXPERIMENTAL
Intervention: TUVRP
Number of subjects: 96
Study 11135382 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises (PME)
Number of subjects: 58
Study 11135382 — intervention group
Group type: COMPARATOR
Intervention: Control group (A)
Number of subjects: 58
Study 9554801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 200 mg orally daily for 2 weeks
Number of subjects: 20
Study 7999487 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole 40 mg
Number of subjects: 150
Study 7999487 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg
Number of subjects: 150
Study 7999487 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine 40 mg
Number of subjects: 150
Study 3243932 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprofen with food (standard meal)
Number of subjects: 24
Study 3243932 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprofen with milk (8-ounce glass)
Number of subjects: 24
Study 3243932 — intervention group
Group type: COMPARATOR
Intervention: Suprofen in fasted state
Number of subjects: 24
Study 30104006 — intervention group
Group type: EXPERIMENTAL
Intervention: CTRT (RT + weekly cisplatin), n = 94
Number of subjects: 180
Study 30104006 — intervention group
Group type: COMPARATOR
Intervention: RT alone, n = 86
Number of subjects: 180
Study 26632091 — intervention group
Group type: EXPERIMENTAL
Intervention: IPX066 (carbidopa-levodopa extended-release capsules)
Number of subjects: 171
Study 26632091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 25634565 — intervention group
Group type: EXPERIMENTAL
Intervention: IV methylprednisolone (2 mg/kg loading dose, 1 mg/kg/d continuous infusion on days 1‐7, tapered on days 8‐14)
Number of subjects: 35
Study 25634565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 24231627 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus pemetrexed (400 mg/m2 at first dose and 250 mg/m2 weekly thereafter)
Number of subjects: 938
Study 24231627 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed alone (500 mg/m2)
Number of subjects: 938
Study 24231627 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m2) with cetuximab
Number of subjects: 938
Study 24231627 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2) alone
Number of subjects: 938
Study 20928842 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 250
Study 20928842 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 250
Study 18509620 — intervention group
Group type: EXPERIMENTAL
Intervention: Benfotiamine supplementation
Number of subjects: 0
Study 16980115 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy (coronary angiography and revascularisation within 7 days from admission)
Number of subjects: 2457
Study 16980115 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 2457
Study 16980115 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive primarily medical strategy
Number of subjects: 2457
Study 12614088 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin and mineral supplement
Number of subjects: 130
Study 12614088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 12614088 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin and mineral supplement among diabetic participants
Number of subjects: 130
Study 12614088 — intervention group
Group type: COMPARATOR
Intervention: Placebo among diabetic participants
Number of subjects: 130
Study 10472515 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 36
Study 10472515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8857325 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum eosinophil peroxidase (S-EPO)
Number of subjects: 154
Study 8857325 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum eosinophil cationic protein (S-ECP)
Number of subjects: 154
Study 8857325 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood eosinophil count (B-Eos)
Number of subjects: 154
Study 8857325 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma symptom score
Number of subjects: 154
Study 1764940 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion of NORPLANT implants with scalpel
Number of subjects: 843
Study 1764940 — intervention group
Group type: COMPARATOR
Intervention: Insertion of NORPLANT implants without scalpel
Number of subjects: 843
Study 6804654 — intervention group
Group type: EXPERIMENTAL
Intervention: Opsite catheter dressings
Number of subjects: 261
Study 6804654 — intervention group
Group type: COMPARATOR
Intervention: Standard gauze/tape dressings
Number of subjects: 261
Study 31539328 — intervention group
Group type: COMPARATOR
Intervention: Single Tourniquet (ST)
Number of subjects: 100
Study 31539328 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Tourniquet (DT)
Number of subjects: 100
Study 31539328 — intervention group
Group type: COMPARATOR
Intervention: Non-attending inserters
Number of subjects: 100
Study 31539328 — intervention group
Group type: EXPERIMENTAL
Intervention: Attending inserters
Number of subjects: 100
Study 27913306 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant 30 mg
Number of subjects: 33
Study 27913306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 27252756 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze dried Lactobacillus acidophilus, Bifidobacterium longum, Bifidobacterium bifidum and Bifidobacterium lactis (Group A)
Number of subjects: 33
Study 27252756 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze dried lactic acid bacillus (Group B)
Number of subjects: 33
Study 27252756 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder (Group C)
Number of subjects: 33
Study 25298016 — intervention group
Group type: COMPARATOR
Intervention: Nutrition psychoeducation (NPC)
Number of subjects: 89